Literature DB >> 8541473

Experimental deposition of Alzheimer amyloid beta-protein in canine leptomeningeal vessels.

R Prior1, D D'Urso, R Frank, I Prikulis, G Pavlakovic.   

Abstract

To study the pathogenesis of cerebral amyloid angiopathy (CAA), organ cultures of canine leptomeninges were incubated with fluorescein-conjugated amyloid beta-protein (FA beta, residues 1-40; 10 nM to 200 microM). Fluorescence microscopy showed focal and dose-dependent FA beta binding to blood vessels affected by CAA at FA beta-concentrations as low as 10 nM. The new A beta deposits appeared to be extracellular and were localized to the middle and outer layers of leptomeningeal arterioles. FA beta partially co-localized with apolipoprotein E (ApoE) as revealed by confocal microscopy, suggesting that A beta in situ binds to ApoE. Young dogs or old dogs without CAA showed no deposition of FA beta. Our results indicate that after initiation of CAA pathology, physiological concentrations of soluble A beta are sufficient to sustain its further deposition and therefore the progression of CAA.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8541473     DOI: 10.1097/00001756-199509000-00010

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  3 in total

1.  Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons.

Authors:  J Van Dorpe; L Smeijers; I Dewachter; D Nuyens; K Spittaels; C Van Den Haute; M Mercken; D Moechars; I Laenen; C Kuiperi; K Bruynseels; I Tesseur; R Loos; H Vanderstichele; F Checler; R Sciot; F Van Leuven
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  Neurobiology of the aging dog.

Authors:  Elizabeth Head
Journal:  Age (Dordr)       Date:  2010-09-16

3.  Selective binding of soluble Abeta1-40 and Abeta1-42 to a subset of senile plaques.

Authors:  R Prior; D D'Urso; R Frank; I Prikulis; S Cleven; R Ihl; G Pavlakovic
Journal:  Am J Pathol       Date:  1996-06       Impact factor: 4.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.